Active, not recruitingEarly Phase 1NCT07182838

Proof-of-Concept Clinical Pharmacology Trial for HIV Antigen Presentation Therapeutic Biologic Mix

Studying Acquired immunodeficiency

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Principal Investigator
HAN XU, MD/PhD/FAPCR
Medicine Invention Design Incorporation - IRB00009424
Intervention
HIV Therapeutic Biologic Mix - HIV GP160 plus BCG Vaccine Mix for percutaneous use(biological)
Enrollment
20 target
Eligibility
24-64 years · All sexes
Timeline
2025 – 2026

Study locations (1)

Collaborators

UnitedHealthcare

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07182838 on ClinicalTrials.gov

Other trials for Acquired immunodeficiency

Additional recruiting or active studies for the same condition.

See all trials for Acquired immunodeficiency →

← Back to all trials